ANX anadis limited

Anadis For the Little Black Book

  1. 470 Posts.
    I know biotech companies are not sexy right now, but this is one to keep an eye on. They have an interesting portfolio of products in phase II trials plus a production arm and some great ongoing research. Not many shares out there either...
    AnnaP

    This announcement just outANADIS LIMITED 2002-10-07 ASX-SIGNAL-G

    HOMEX - Melbourne

    +++++++++++++++++++++++++
    Anadis Limited is pleased to announce that we have joined with the
    Department of Defence to further develop a breakthrough technology
    that has potential to provide effective short-term protection for
    military personnel against a range of biological warfare threats,
    including anthrax and plague, as well as protecting civilian
    emergency workers against diseases such as tuberculosis and
    Legionnaire's disease.

    Anadis laboratory trials have shown the technology is highly
    successful in protecting the lungs against a Yersinia bacterium
    closely related to the species that causes plague. Anadis has lodged
    a provisional patent on the discovery.

    This is a revolutionary discovery: the bacteria that cause plague and
    anthrax have been very difficult to vaccinate against or to treat
    with antibiotics because they survive within immune cells in the
    lungs.

    The Department of Defence has asked Anadis to work with it in a joint
    research program that combines Anadis' binding protein technologies,
    bioshielding technologies and protective respiratory technologies
    with the expertise of scientists from the Defence Science and
    Technology Organisation.

    Anadis and Defence scientists are now designing the joint project and
    will work together to produce assays, diagnostics and therapies of
    interest to the Australian Defence Force. The technologies are also
    highly likely to be of interest to Australia's military allies.

    Anadis also believes that the technology could have other potential
    uses in the civilian area, and is currently exploring a number of
    other applications.

    Additionally, Anadis is currently involved in negotiating with The
    Development Centre for Biotechnology in Taiwan the potential for
    Anadis' technologies to be applied for the potential treatment of
    Enterovirus 71 - a virus prevalent in children in Asia.


    C Graham
    MANAGING DIRECTOR & CEO


    For further information Contact:

    Conor Graham or Dr Grant Rawlin
    Telephone : 03 9358 6388
    Facsimile: 03 9358 6399
    Email: [email protected]


 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.